BackConnect Biopharma Holdings Overview

Connect Biopharma Holdings Total Current Liabilities

Latest total current liabilities for CNTB: $14M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$13.61M
60.87% YoYΔ $5.15M vs prior year quarter

Peer average

Loading

Connect Biopharma Holdings Total Current Liabilities History

Loading

Connect Biopharma Holdings vs. peers: Total Current Liabilities Comparison

Loading

Connect Biopharma Holdings Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Connect Biopharma Holdings (CNTB) FAQ

Connect Biopharma Holdings posts a total current liabilities of $14M as of December 2025. That compares with $8.5M in the prior-year period — up 60.9% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Connect Biopharma Holdings's total current liabilities was $8.5M. The latest reading is $14M — a 60.9% year-over-year increase (period ending December 2025). Use the history and growth charts on this page for a longer lookback.

Total Current Liabilities is one piece of Connect Biopharma Holdings's financial statement story. At $14M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CNTB's total current liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Connect Biopharma Holdings's other metric pages and overview cover the third.

Judging Connect Biopharma Holdings against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in total current liabilities easier to interpret. Start with $14M here, then scan peer and history charts to see if the gap is persistent.